Filing Flows › Health Care › Xenetic Biosciences (XBIO)
Xenetic Biosciences (XBIO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Xenetic Biosciences (XBIO) Q2 2026 earnings results →
Q2 2026 Revenue up 12% year over year to $661K · 141¢ of every $1 of revenue lost · operating margin -147.1%
Xenetic Biosciences made $661K in Q2 2026 (+12% Y/Y). Operating margin -147.1%, net loss $930K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $661K in Q2 2026, up 12% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $1.0M, an operating margin of -147.1%. Total costs grew 24% against revenue growth of 12%. The fastest-growing cost line was General & admin (+64%). The quarter ended with a net loss of $930K, wider than the previous quarter's $456K loss.
Operating cash flow was −$875K. Non-cash charges added back $52K of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $661K | +12% | -147.1% | −$930K | −$875K |
| Q1 2026 | 10-Q | May 12, 2026 | $807K | +36% | -62.2% | −$456K | −$536K |
| Q4 2025 | 10-K | Mar 12, 2026 | $766K | +18% | -81.3% | −$579K | −$243K |
| Q3 2025 | 10-Q | Nov 12, 2025 | $1.0M | +67% | -53.0% | −$510K | −$658K |
| Q2 2025 | 10-Q | Aug 12, 2025 | $590K | -19% | -122.8% | −$689K | −$384K |
| Q1 2025 | 10-Q | May 13, 2025 | $593K | +16% | -158.9% | −$903K | −$1.0M |
| Q4 2024 | 10-K | Mar 18, 2025 | $649K | -3% | -169.4% | −$1.1M | −$674K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
In its own words, from its 8-K, filed Aug 7, 2026.
Xenetic Biosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +12% against the peers' median +10%. Operating margin: -147.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| XBIO Xenetic Biosciences | Q2 2026 | $661K | +12% | -147.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Xenetic Biosciences 10-Q on SEC EDGAR · CIK 1534525 · Pharmaceutical Preparations
13F: who owns XBIO and who is buying
More on XBIO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results